ストックスクリーナーアプリを入手
13.17
2.29%
-0.34
前日終値:
$13.51
開ける：
$13.11
24時間の取引高:
180.05K
Relative Volume:
0.23
時価総額：
$857.71M
収益：
-
当期純損益:
$-119.67M
株価収益率:
-4.8242
EPS:
-2.73
ネットキャッシュフロー:
$-97.30M
1週間 パフォーマンス:
-1.93%
1か月 パフォーマンス:
-8.90%
6か月 パフォーマンス:
+29.41%
1年 パフォーマンス:
+11.58%
1日の値動き範囲:
$12.59
$13.80
1週間の範囲:
$12.59
$13.80
52週間の値動き範囲:
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
名前
Mineralys Therapeutics Inc
セクター
電話
(888) 378-6240
住所
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
13.16 | 859.66M | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.86 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.13 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.94 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.75 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
300.44 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-11 | 開始されました | Jefferies | Hold |
| 2024-07-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-02 | 開始されました | Goldman | Buy |
| 2023-03-07 | 開始されました | BofA Securities | Buy |
| 2023-03-07 | 開始されました | Credit Suisse | Outperform |
| 2023-03-07 | 開始されました | Evercore ISI | Outperform |
| 2023-03-07 | 開始されました | Guggenheim | Buy |
| 2023-03-07 | 開始されました | Stifel | Buy |
| 2023-03-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Mineralys Therapeutics Q2 2025: Unraveling Contradictions in Manufacturing, Trials, and Market Strategies - AInvest
Mineralys Therapeutics Reports Positive Q2 2025 Results - TipRanks
Transcript : Mineralys Therapeutics, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Earnings call transcript: Mineralys Therapeutics beats Q2 2025 EPS forecast, stock rises - Investing.com Nigeria
Mineralys Therapeutics, Inc. SEC 10-Q Report - TradingView
Mineralys Therapeutics Q2 GAAP Loss Narrows - MarketScreener
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Mineralys Therapeutics to Announce Q2 Financial Results on August 12 - MSN
Mineralys Therapeutics CFO & Secretary Adam Levy Sells 36% Of Holding - simplywall.st
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 - The Manila Times
Momentum Screeners Rank Mineralys Therapeutics Inc. in Top 5 TodaySwing Trading Plan With Smart Signals in Review - beatles.ru
Support Zone Holds Steady for Mineralys Therapeutics Inc. After DipLow Capital High Return Stock Plans Reviewed - metal.it
Mineralys Therapeutics to Announce Second Quarter 2025 - GlobeNewswire
What drives Mineralys Therapeutics Inc. stock priceAchieve consistent profits with smart trading - Jammu Links News
How many analysts rate Mineralys Therapeutics Inc. as a “Buy”Explosive trading growth - Jammu Links News
What are Mineralys Therapeutics Inc. company’s key revenue driversBuild a diversified portfolio for risk management - Jammu Links News
What catalysts could drive Mineralys Therapeutics Inc. stock higher in 2025Unlock exclusive trading tools and resources - Jammu Links News
Mineralys Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough investment performance - Jammu Links News
Is Mineralys Therapeutics Inc. stock overvalued or undervaluedBuild wealth steadily with smart stock selection - Jammu Links News
What is the dividend policy of Mineralys Therapeutics Inc. stockCapitalize on market trends with confidence - jammulinksnews.com
How volatile is Mineralys Therapeutics Inc. stock compared to the marketMaster the art of timing market moves - Jammu Links News
How strong is Mineralys Therapeutics Inc. company’s balance sheetCapitalize on fast-moving trading opportunities - Jammu Links News
Is it the right time to buy Mineralys Therapeutics Inc. stockBuild a balanced portfolio for long-term success - Jammu Links News
CFO & Secretary Of Mineralys Therapeutics Sold 36% Of Their Shares - 富途牛牛
Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and Development of Newer Therapies During the Study Period (2020-2034) | DelveInsight - Yahoo Finance
Mineralys Therapeutics Insider Sold Shares Worth $1,077,477, According to a Recent SEC Filing - 富途牛牛
Mineralys Therapeutics CFO Adam Levy sells $1m+ in shares By Investing.com - Investing.com Australia
Mineralys Therapeutics CFO Adam Levy sells $1m+ in shares - Investing.com
Mineralys CFO Sells 12946 Shares at $14.04/Share on 2025-07-28 - AInvest
What analysts say about Mineralys Therapeutics Inc. stock outlookRisk Adjusted Technical Entry Plan Gains Followers - beatles.ru
Why Mineralys Therapeutics Inc. stock attracts strong analyst attentionNews Based Entry Opportunity Alerts Detected - beatles.ru
Will Mineralys Therapeutics Inc. stock split in the near futureTrend Analysis for Safer Trades Gains Popularity - metal.it
Aldosterone Synthase Inhibitors Market is evolving rapidly - openPR.com
Intrinsic Value of Mineralys Therapeutics Inc. Stock: Is It Undervalued or OvervaluedAccurate Technical Trend Reversal Picks Detected - metal.it
Is Mineralys Therapeutics Inc. a growth stock or a value stockExceptional market positioning - Jammu Links News
Why is Mineralys Therapeutics Inc. stock attracting strong analyst attentionOutstanding trading profits - Jammu Links News
What are the latest earnings results for Mineralys Therapeutics Inc.Get real-time updates on market trends - Jammu Links News
What are the technical indicators suggesting about Mineralys Therapeutics Inc.Unrivaled growth potential - Jammu Links News
What is Mineralys Therapeutics Inc. company’s growth strategyPowerful market insights - jammulinksnews.com
Published on: 2025-07-27 22:40:23 - Jammu Links News
Mineralys Therapeutics Inc (MLYS) 財務データ
収益
当期純利益
現金流量
EPS
Mineralys Therapeutics Inc (MLYS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Levy Adam Scott | CFO and Secretary |
Jul 28 '25 |
Sale |
14.04 |
12,946 |
181,803 |
193,666 |
| Levy Adam Scott | CFO and Secretary |
Jul 29 '25 |
Sale |
14.00 |
807 |
11,302 |
192,859 |
0.50%
0.26%
大文字化:
|
ボリューム (24 時間):